The mean serum fibronectin level of normal subjects, measured by radio-immunoassay, was 363 micrograms/ml (+/- 72 micrograms/ml; 1 SD). The levels were lower in younger subjects and in females using oral contraceptives. In most patients admitted to a respiratory intensive care unit fibronectin levels were low initially, and only remained low in those cases in which severe complications developed. There were no rapid fluctuations of fibronectin levels measured on a daily basis, suggesting therefore that a consumptive reduction of fibronectin is not a feature. The fibronectin molecule itself has abnormal properties in pathological cases and is poorly precipitable by heparin. These studies do not support the proposal that administration of plasma or cryoprecipitates would be beneficial chiefly because of the fibronectin content.

Download full-text PDF

Source

Publication Analysis

Top Keywords

fibronectin levels
12
normal subjects
8
patients admitted
8
admitted respiratory
8
respiratory intensive
8
intensive care
8
care unit
8
fibronectin
7
levels normal
4
subjects patients
4

Similar Publications

Irisin is a newly discovered 12 kDa messenger protein involved in energy metabolism. Irisin affects signaling pathways in several types of cancer; however, the role of irisin in metastatic melanoma (MM) has not been described yet. We explored the biological effects of irisin in in vitro models of MM cells (HBL, LND1, Hmel1 and M3) capable of the oncogenic activation of BRAF.

View Article and Find Full Text PDF

Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths globally, with a persistently low five-year survival rate of only 14-17%. High rates of metastasis contribute significantly to the poor prognosis of NSCLC, in which inflammation plays an important role by enhancing tumor growth, angiogenesis, and metastasis. Targeting inflammatory pathways within cancer cells may thus represent a promising strategy for inhibiting NSCLC metastasis.

View Article and Find Full Text PDF

Investigation of Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer.

Biology (Basel)

December 2024

Department of Medical Biology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkey.

HER2-positive breast cancer has an aggressive tumour progression among breast cancers characterized by the overexpression of HER2. Trastuzumab is an FDA-approved drug and has significantly improved outcomes for patients; however, drug resistance remains a major challenge. Tumour heterogeneity, describing genetic, epigenetic, and phenotypic differences within and between tumours, complicates tumour treatment and contributes to drug resistance.

View Article and Find Full Text PDF

Idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung disease have limited treatment options. Fibroblasts are key effector cells that sense matrix stiffness through conformation changes in mechanically sensitive receptors, leading to activation of downstream profibrotic pathways. Here we investigate the role of Piezo2, a mechanosensitive ion channel, in human and mouse lung fibrosis, and its function in myofibroblast differentiation in primary human lung fibroblasts (HLFs).

View Article and Find Full Text PDF

AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility.

Sci Rep

January 2025

Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.

Pancreatic ductal adenocarcinoma lacks suitable biomarkers for early diagnosis of disease. In gene panels developed for early diagnosis of pancreatic cancer, high AHNAK2 mRNA expression was one possible biomarker. In silico analysis of published human sample datasets (n = 177) and ex vivo analysis of human plasma samples (n = 30 PDAC with matched 30 healthy control) suggested AHNAK2 could be a diagnostic biomarker.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!